The purpose of this clinical experiment is to assess how well autogenous tooth bone grafting preserves the alveolar socket after surgical tooth extraction. Before being inserted into the socket, the graft is made from the patient's own extracted tooth and ground into a particle. Twenty Yemeni patients who needed their teeth extracted are included in the trial, and they will be followed up with clinical and radiographic procedures using cone-beam computed tomography (CBCT) for six months. The primary objective is to ascertain whether the autogenous dental bone graft can preserve the height, width, and density of alveolar bone, offering a secure, affordable, and biocompatible substitute for traditional grafting materials.

This interventional clinical study investigates the role of autogenous tooth bone graft in alveolar socket preservation after surgical tooth extraction. The extracted tooth is cleaned, dried, processed into particulate graft material manually using bone crusher, and disinfect and treated using (NaOH) and (Na CL). The graft particles are immediately placed into the fresh extraction socket and sutured. Twenty Yemeni patients requiring impacted lower third molar and upper canine teeth surgical extractions will be included. The healing process will be evaluated both clinically and radiographically over a 6-month period. Cone-beam computed tomography (CBCT) scans will be used to assess bone density and alveolar ridge dimensions before extraction and at six months' post-intervention. The study aims to determine whether autogenous tooth bone grafts can effectively reduce post-extraction alveolar bone resorption and maintain ridge dimensions, supporting their potential use as an autologous, biocompatible, and economically feasible graft material for clinical socket preservation.

Inclusion Criteria:

• - Absence of systemic diseases.
• Very good to accepted oral hygiene.
• Patients with impacted teeth requiring extraction.
• Patients between the ages of 16 and 50.
• No history of smoking.
• No history of any other drug use.
• Patients who were cooperative, motivated, to attend the follow-up and maintenance visits.

Exclusion Criteria:

• Systemic conditions or pharmacological therapies that could be an absolute contraindication for the intervention (such as un controlled diabetics, immunocompromised states, or treatment with oral or parenteral bisphosphonates).
• Poor oral hygiene.
• Acute exacerbation of chronic infection like pain or swelling.
• Pregnant women, children, elderly (>60 years), physically and mentally challenged, terminally and seriously ill.
• Hight Smoking tendency.
• Patients who refused to participate in the trial.
• Uncooperative Patients who won't be able to maintain the follow up visits

"We will share anonymized individual participant data (IPD), including baseline characteristics, clinical assessments, and key outcome measures (alveolar bone height, width, and density) collected before and after the autogenous tooth bone graft intervention. Access to the data will be granted to qualified researchers who meet the criteria for data sharing and comply with the applicable data use agreement."

"IPD and supporting information will be made available starting 12 months after the completion of the study. The data will be accessible for a period of 5 years."

"Access to IPD and supporting information will be granted to qualified researchers who submit a data request via the ClinicalTrials.gov platform. Researchers must meet the criteria outlined in the Data Use Agreement, which ensures that the data will be used responsibly and for research purposes only."